Preclinical discovery and clinical development of encorafenib for the treatment of melanoma
Authors:
- 28 July 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 15 (12) , 1373-1380
Abstract
Nearly 50% of patients with metastatic melanoma harbor a BRAFV600-mutation, which can be targeted with the use of BRAF and MEK inhibitors, either in the front-line or treatment-refractory setting. ...Keywords
This publication has 39 references indexed in Scilit:
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary resultsJournal of Translational Medicine, 2014
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical ImpactClinical Cancer Research, 2014
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapyCancer Discovery, 2014
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Melanoma: from mutations to medicineGenes & Development, 2012
- Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitorCancer Research, 2012
- Melanoma: New Insights and New TherapiesJournal of Investigative Dermatology, 2012
- Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic MelanomaJournal of Clinical Oncology, 2011
- Management of Cutaneous MelanomaNew England Journal of Medicine, 2004
- Mutations of the BRAF gene in human cancerNature, 2002